

# Efficacy, safety and discontinuation of rilpivirine and cabotegravir in HIV-1 virologically suppressed adults: a multicenter observational study in Tuscany (LAHIV study)

F. Lagi<sup>1</sup>, G. Formica<sup>2</sup>, E. Francalanci<sup>2</sup>, M. Fognani<sup>2</sup>, R. Paggi<sup>2</sup>, G. Gasparro<sup>2</sup>, M. Piccica<sup>3</sup>, A. Pampaloni<sup>4</sup>, D. Messeri<sup>5</sup>, B. Rossetti<sup>6</sup>, M. Fabbiani<sup>7</sup>, S. Costarelli<sup>8</sup>, E. Riguccini<sup>9</sup>, G. Sarteschi<sup>10</sup>, M. De Gennaro<sup>11</sup>, P. Corsi<sup>1</sup>, M. Pozzi<sup>1</sup>, G. Sterrantino<sup>2</sup>, M. Tumbarello<sup>7</sup>, P. Blanc<sup>5</sup>, F. Bartalesi<sup>3</sup>, D. Aquilini<sup>4</sup>, C. Nencioni<sup>6</sup>, S. Luchi<sup>11</sup>, D. Tacconi<sup>9</sup>, S. Sani<sup>8</sup>, A. Vincenti<sup>10</sup>, A. Bartoloni<sup>1-2</sup>

1) Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze 2) Dipartimento di medicina sperimentale e clinica, Università degli studi di Firenze 3) Ospedale Santa Maria Annunziata, USL Toscana Centro 4) Azienda Ospedaliera Prato, USL Toscana Centro 5) Azienda Ospedaliera Pistoia, USL Toscana Centro 6) Azienda Ospedaliera Grosseto, USL Toscana Sud-Est 7) Azienda Ospedaliero-Universitaria Siena, Università degli Studi di Siena 8) Azienda Ospedaliera Livorno, USL Toscana Nord-Ovest 9) Azienda Ospedaliera Arezzo, USL Toscana Sud-Est 10) Nuovo Ospedale Apuane, USL Toscana Nord-Ovest 11) Azienda Ospedaliera Lucca, USL Toscana Nord-Ovest

## Introduction/Summary

- Cabotegravir (CAB) + rilpivirine (RPV), available in Italy from June 2022, dosed intramuscularly every 2 months is the first long-acting (LA) regimen used to maintain HIV-1 virological suppression.
- We evaluated the efficacy, safety and durability of this regimen.

#### **Study Design**


- It is an observational multicenter study in which 10 out of 11 Tuscan Infectious Disease units participated.
- We included all virologically suppressed (HIV-RNA <50 cp/mL) persons living with HIV (PLWH) older than 18 years who initiated CAB+RPV with at least one followup visit.
- Discontinuation was defined as a regimen switch or 2 consecutive missed injections.
   Virological failure (VF) was defined as two consecutive HIV-RNA >50 copies/mL detections or a single HIV-RNA >50 copies/ mL followed by ART modification
- Participants were monitored after the first injection until the date of CAB+RPV discontinuation, death, or last visit to the center.
- The study period is from 10/09/2022 to 20/03/2024
- The primary outcomes were "discontinuation due to all causes". The secondary outcome was the assessment of safety.

#### Methods

- Descriptive analysis was employed to illustrate population characteristics.
- Categorical variables were evaluated with X2/Fisher's exact test. Continuous variables with Mann-Whitney test.
- The cumulative risk of discontinuation was assessed using Kaplan–Meier curves.
- The statistical test was considered significant if the p-value was <0.05.</p>

## Results

- We enrolled 102 PLWH. We grouped participants based on their duration of followup: all completed 4 weeks; 77 remained for 12 weeks; 60 for 28 weeks; and 26 reached 44 weeks. [Figure 1]
- The combined at-risk period for analysis totaled 55,493 days, with a median follow-up of 28 weeks [IQR 11-44]



#### DEMOGRAPHIC

Of the participants, 82 (80.4%) were male, with a median age of 51 years (IQR, 42-57). Participants discontinuing LA showed no clinical/demographic differences from those continuing, except a shorter time from the last detectable HIV-RNA and CAB+RPV introduction and more often lacking the genotype before switching; [Table 1]

with HIV-RNA level <50 copies/mL switching to RPV+CAB in 10 out 11 infectious diseases units in Tuscany, Italy.							
diseases units in Tuscany,	, Italy. On CAB+RPV (n=93)		Discontinue d (n=9)		р	TOTAL (n=102)	
Italians, n (%)	79	84.9	9	100		88	86.2
Gender, n (%)					····-		
• Female	15	16.1	4	44.4		19	18.6
Male	77	82.8	5	55.6		82	80.4
<ul> <li>Transgender</li> </ul>	1	1.1	0			1	1
Age at entry, median [IQR]	51	[42-57]	52	[38-56]	0.727	51	[42-57]
Risk of HIV transmission, n (%)					-		
Heterosexual	25	26.8	4	44.4		29	28.4
• MSM	43	46.2	5	55.6		48	47.1
<ul> <li>Intravenous drug users</li> </ul>	10	10.7	0	-		10	9.8
Other/Not     known	15	16.1	0	-		15	14.7
Years of undetectable viremia, median [IQR]	4.9	[1-9]	0.2	0.2-2.5	0.006	4	[1-9]
AIDS diagnosis, n (%)	12	12.9	1	11.1	0.878	13	12.7
HBc Ab, n (%)	20	24.4	1	11.1	0.369	21	23.1
HIV-RNA Zenit, Log <sub>10</sub> copies/mL, median [IQR]]	4.8	[4.4-5.4]	5.0	4.9-5.5	0.353	4.9	[4.4-5.4]
Nadir CD4 (cells/mL), median [IQR]	328	[156-453]	237	97-324	0.220	313	[147-435]
Years of HIV, median [IQR]	12	6-19	20	9-23	0.235	12	6-20
CD4+ T cells at baseline/µL, median [IQR]	875	[640-1085]	760	652- 836	0.425	857	[640-1080]
CD4/CD8, median [IQR]	1.1	[0.7-1.5]	0.9	0.7-1.3	0.535	1.1	[0.7-1.5]
Type of pre-switch regimen							
NNRTI	38	40.8	5	55.6		43	42.1
• PI	11	11.8	0	-		11	10.8
• INSTI	66	70.9	7	77.7		77	75.4
Number of previous ART regimens, median [IQR]	4	[2-5]	4	3-6	0.322	4	[2-5]
Pre-switch regimen containing rilpivirine, n (%)	34	36.6	5	55.6	0.263	39	28.2
Pre-switch regimen containing dolutegravir, n (%)	42	45.2	7	77.8	0.061	49	48.1
Available genotype before the switch, n (%)	64	68.8	3	33.3	0.008	67	65.7
Reasons for LA introduction							
Simplification	84	90.3	8	88.9		92	90.2
Toxicity	1	1	0	-		1	1
Other	8	8.7	1	11.1		9	8.8

Previous regimen	BMI	NNRTI or INSTI	Cause	W E	Post- regimen
		mutations on the last genotype		E K	
3TC/DTG	N/A	N/A	High fever and joint pain, Walking impairment	4	3TC/DTG
RPV/DTG	N/A	Not detected	Rash	28	RPV/DTG
3TC/DTG	29.5	98G 106I 108I 181V	Virological Failure	4	T/F/DRVc
RPV/DTG	20.2	N/A	General malaise	4	RPV/DTG
3TC/DTG	25.3	N/A	Depression	4	3TC/DTG
RPV/DTG	22	N/A	Lost-to follow-up	12	//
T/F/RPV	23	Not detected	Panic attacks	12	T/F/RPV
T/F/RPV	23.4	N/A	Excessive clinic visits	28	T/F/RPV
3TC/DTG	21	N/A	Weight gain of 10kg, worsening of depressive symptoms	44	3TC/DTG

The discontinuation rate due to all causes was 16.2 x 100 py [95%CI 8.4-31.2]. This rate is higher compared to to RCTs but it could be overstated due to short follow-up times; a 4-week timepoint is the last observation for over 25% of patients.

0.75-				~ <u> </u>	Figure 2. Probability of remaining free from treatment discontinuation for all
0.50					causes in adults with HIV-1 ART experienced with HIV-RNA level <50 copies/mL switching to
0.25					RPV+CAB in 10 out 11 infectious diseases units in Tuscany, Italy.
0	10	20 Weeks	30	40	

# SAFETY

Apart from the 6 discontinuations due to adverse events (10.8 x 100 py 95%Cl 4.8-241), we observed 76 adverse events of grade 1: 63 local reactions and 13 systemic ones. Over time, the frequency of these reactions lessened, as shown in Figure 2. [Figure 3]



# DISCONTINUATIONS

Overall, we observed 9 discontinuations: 6 from adverse events, 1 by patient choice, 1 from being lost to follow-up, and 1 from VF. The participant who experienced VF had pre-existing high-level mutations for RPV. The genotype at failure showed no mutations for CAB and the patient's virus was suppressed again with TAF/FTC/DRVc. Notably, 4 of the 6 adverse events occurred within the initial 4 weeks and spontaneously regressed after the LA discontinuation. [Table 2]

## Conclusion

- Our preliminary findings suggest the RPV+CAB effectively sustains virological suppression: the only VF observed was linked to a pre-existing RPV resistance.
- Safety is acceptable; only 5% stopped due to toxicity. However, data could be skewed by the small sample and short follow-up. The decrease in mild local adverse reactions with use may indicate an increasing adaptation of patients to the regimen.